AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05204810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: During the study sessions, blood sampling is performed from the arterial blood line at different time points (5min, 60min, 240min and at the dialysis end)
Study NCT05204810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scanning of hemodialyzer with micro-computed tomography
Description: After the study sessions, the used hemodialyzers are scanned using a gold standard micro computed tomography technique.
Study NCT05161299 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery (across all specialities)
Description: Surgery performed by a surgeon in an operating theatre during the patient inclusion period
Study NCT04954599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-506
Description: CP-506 is a hypoxia-activated DNA alkylating agent specifically designed to have a bystander effect, aqueous solubility, oral bioavailability, and no off-mechanism activation by the human aerobic reductase AKR1C3
Study NCT04954599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Antineoplastic agent, ATC Code: LO1X A02
Study NCT04954599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: Drug that blocks immune checkpoint proteins: PD-1, PD-L1, CTLA-4
Study NCT06217757 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
Study NCT06217757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT06217757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as intravenous infusion at a dose of 25 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Study NCT06217757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugemalimab
Description: Sugemalimab will be administered by intravenous infusion at a dose of 1200mg on Day 1 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.
Study NCT06217757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered orally at a dose of 150mg qod Day 1,3,5,7 or 150 mg qd/150 mg bid/300mg in the morning and 150mg in the evening/300 mg bid on Day 1-7 of each 21-day cycle for a maximum of 2 years or progressive disease or intolerable toxicity.
Study NCT05565729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY3471851
Description: Administered SC.
Study NCT05565729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC.
Study NCT05565729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT05565729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Administered orally.
Study NCT05648162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture
Description: Electrical acupuncture (2Hz, 150 μs) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
Study NCT05648162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Electrical acupuncture (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
Study NCT05648162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS (1mA) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
Study NCT05648162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham tDCS
Description: tDCS (no electricity) once daily (five times a week), for 20 minutes each session, totaling 20 sessions.
Study NCT05648162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NDT-Bobath Rehabilitation
Description: NDT-Bobath Rehabilitation once daily (five times a week), for 30 minutes each session, totaling 20 sessions.
Study NCT05648162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NDT-Bobath Rehabilitation
Description: NDT-Bobath Rehabilitation once daily (five times a week), for 30 minutes each session, totaling 20 sessions.
Study NCT05695781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BRM421 Ophthalmic Solution
Description: A topical drop of BRM421 ophthalmic solution.
Study NCT06191367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive Spirometer Device
Description: is a handheld medical device used to help patients improve the functioning of their lungs. By training patients to take slow and deep breaths, this simplified spirometer facilitates lung expansion and strengthening. Patients inhale through a mouthpiece, which causes a piston inside the device to rise. This visual feedback helps them monitor their inspiratory effort. Incentive spirometers are commonly used after surgery or other illnesses to prevent pulmonary complications.
Study NCT06191367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chest Physiotherapy
Description: 1. Breathing exercise.~2. Postural drainage.~3. Percussion.~4. Coughing.~5. Vibration.
Study NCT05695781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: A topical drop of vehicle (minus active) ophthalmic solution.
Study NCT06299384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LyssnCrisis
Description: LyssnCrisis is an AI-based coding and feedback tool for implementation in crisis counseling settings, training counselors (call-takers) in suicide risk assessment skills.
Study NCT06152146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave Therapy
Description: Each therapy session will last about 20 minutes, during which 1,440 shockwaves will be applied to the penis via the left and right crus (shaft near the base)
Study NCT06152146 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SHAM shockwave therapy
Description: Each therapy session, lasting about 20 minutes, will deliver 1440 SHAM shockwave therapy applied to the penis via the left and right crus (shaft near the base)
Study NCT05390567 — intervention group
Intervention type: BEHAVIORAL
Intervention: Participant Choice of HPV Self-Test
Description: Opportunity for participants to complete the HPV self-test in a non-clinical setting to be returned via a mailer or courier servie.
Study NCT06191367 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Chest Physiotherapy
Description: 1. Breathing exercise.~2. Postural drainage.~3. Percussion.~4. Coughing.~5. Vibration.
Study NCT05073575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: After local anesthesia, an access flap will be prepared. Scaling and root planning will be performed combining the use of metal curettes and power-driven instrumentation by means of ultrasonic scaler.~Hyaluronic acid gel will be applied to exposed roots surface, followed by a tension-free primary closure of the surgery wound by means of 5-0 monofilament (polypropylene) non-resorbable suturing material.
Study NCT05390567 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey: Participant cancer history and cervical cancer prevention/screening knowledge
Description: Asking women to respond to questions about their cancer history and knowledge of cervical cancer prevention and screening.
Study NCT05390567 — intervention group
Intervention type: BEHAVIORAL
Intervention: Participant Choice of Standard of Care in-clinic Pap-test
Description: Participant choice of cervical cancer screening method with either a SOC in-clinic pap test or HPV self-test
Study NCT06573450 — intervention group
Intervention type: OTHER
Intervention: questionnaire survey
Description: subjects fill out questionnaires
Study NCT05094531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary prevention programm
Description: This programm aims to adress three dimensions : (i) biophysiology (flexibility of the autonomic nervous system), (ii) psychology (flexibility of coping strategies, sens of mission) and (iii) the social (stigmatization, seeking health care).
Study NCT06578936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal massage andwarm application
Description: Abdominal massage and hot application will be applied to the patients at least 30 minutes after the morning and evening meals (08:30 am, 20:30 pm) for 15 minutes each, similar to the literature. The hot application will be applied to the abdominal area with a hot water thermophore for 15 minutes before the abdominal massage. After the hot application, abdominal massage will be started. In the abdominal massage, which will be applied clockwise to stimulate bowel movements, four basic movements will be used: superficial exertion, deep exertion, petrisage and vibration.
Study NCT05674760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trancutaneous CO2 monitoring (using TCM5 device)
Description: Patients in the Transcutaneous arm will undergo Trancutaneous CO2 monitoring (using TCM5 device)
Study NCT05674760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arterial Blood Gas (ABG) sampling
Description: Arterial Blood Gas (ABG) sampling to monitor CO2 - as per standard practice.
Study NCT04151225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330811
Description: GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.
Study NCT04151225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
Study NCT05073575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No-hyaluronic acid
Description: An access flap will be prepared in order to perform scaling and root planning therapy with the use of metal curettes.~After intervention, a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 monofilament (polypropylene) non-resorbable suturing materia will be performed
Study NCT06574802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERL + air polishing
Description: Er:YAG laser (ERL) plus sub-gingival air polishing treatment
Study NCT06574802 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ERL
Description: ERL treatment
Study NCT04023240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: 68Ga-FAPI is quinoline based PET radiopharmaceutical.~68Ga-FAPI is administered intravenously (IV)
Study NCT04023240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) scan
Description: Participants will have a CT scan for attenuation correction and anatomic localization of PET data.
Study NCT04023240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) scan
Description: PET images will be acquired.
Study NCT06466850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exosome
Description: intra-articular injection is suggested for two times: day 1and day 90
Study NCT05340855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wiidookaage'win Facebook Group
Description: A 30-day Facebook group prototype that is moderated by two women who will post various forms of media addressing opioid recovery, mindfulness, stress management, and resiliency.
Study NCT05627102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Therapeutic Percutaneous Electrolysis an neuromodulation associated with eccentric exercises devices at home.
Study NCT05627102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: Ultrasound pulsatil therapy (US), transcutaneous electric nerve stimulation (TENS) for 20 minutes and associated with eccentric exercises devices at home.
Study NCT04979975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PBO- placebo matching to UB-621
Study NCT04979975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-621 low-dose
Description: fully human anti-HSV mAb
Study NCT04979975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-621 high-dose
Description: fully human anti-HSV mAb
Study NCT06286150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical robot system
Description: SHURUI Single-port surgical robot system
Study NCT04845048 — intervention group
Intervention type: BIOLOGICAL
Intervention: Adsorbed COVID-19 (Inactivated) Vaccine
Description: Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac/Butantan Institute
Study NCT06425549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimekizumab
Description: Study participants receive bimekizumab (BKZ) administered as subcutaneous injection at pre-specified timepoints and dosage regimen during the study.
Study NCT06425549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimekizumab
Description: Study participants receive bimekizumab (BKZ) administered as subcutaneous injection at pre-specified timepoints and dosage regimen during the study.
Study NCT06425549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ustekinumab
Description: Study participants receive ustekinumab (USTE) administered as subcutaneous injection at pre-specified timepoints during the study.
Study NCT06425549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.
Study NCT06425549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.
Study NCT06324266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Cyclophosphamide monotherapy for 2 years.
Study NCT06324266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: Standard risk group MM patients who achieve VGPR or above after initial induction and consolidation therapy and are not suitable transplantation, are maintained with Lenalidomide monotherapy for 2 years.
Study NCT04417686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arterial embolization
Description: arterial embolization of the geniculated arteries for reduction of pain after installation of total knee prosthesis
Study NCT06286605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A-oss and autogenous bone
Description: Horizontal ridge augmentation in one stages approach will be performed using a mix of A-Oss and autologenous bone.
Study NCT06286605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A-oss an LCR-A
Description: Horizontal ridge augmentation in one stages approach will be performed using OssMem with A-Oss and LCR-A
Study NCT06419348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-QULIC-5-P1
Description: Each subject receives a single intravenous injection of 99mTc-QULIC-5-P1.
Study NCT05575960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Adolescents (IPT-A)
Description: Interpersonal Psychotherapy (IPT) is a psychotherapeutic treatment originally developed for treating depression in adults. It is a brief, structured treatment based on the idea of mobilizing the patient's social network, increasing his/her capacity to accept and seek support from others, and to process interpersonal difficulties, in order to improve depressive symptoms. Interpersonal psychotherapy for adolescents (IPT-A) is a version of IPT designed for young people between the age of 12-18 years with depression (Mufson, 2004), and is in many respects similar to IPT although with some modifications (e.g., a few scheduled meetings with parents during the course of treatment).
Study NCT05738993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-178
Description: A single intravenous (IV) infusion at a dose of 420 mg
Study NCT05738993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta
Description: A single intravenous (IV) infusion at a dose of 420 mg
Study NCT05711979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AARC
Description: There will be 10 90min weekly sessions. The first half of each session will consist of health education discussing diet, physical activity and screen time. Participants will set goals for themselves and their families. The investigators will check-in on goals and barriers to achieving goals in each session following the initial session. The second half of the sessions will focus on mindfulness based stress reduction including brief meditation, discussion of mindful eating and mindful parenting. This intervention will adapt an already-existing evidence-based obesity prevention program which has been administered to over 100 families (COACH), and it will add mindfulness-based stress reduction, tailored to African American women.
Study NCT06328764 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CS-101
Description: Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Study NCT04618666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic and open surgery intervention
Description: laparoscopic and open surgery to remove an inflammed appendix in chronic appendicitis
Study NCT05696210 — intervention group
Intervention type: OTHER
Intervention: Transfusion rate of red blood cells
Description: Transfusion rate of red blood cells greater than 7
Study NCT04945148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 2000 to 3000mg/day daily will be started by 6 weeks after histological diagnosis and 7 days before the start of RT-TMZ and will continue until progression.
Study NCT04945148 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation IMRT
Description: 2 Gy x 5 days for 6 weeks to be started 7 days after first administration of Metformin and by 7 weeks after histological diagnosis
Study NCT04945148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m² daily from first to last day of radiation (IMRT) and then 150 to 200 mg/m² x 5 days every 28 days cycle for 12 cycles
Study NCT03915639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri-incisional injection
Description: The surgeons are planned to inject the cocktail mixture or ropivacaine to muscles and the subcutaneous tissue beneath the fixation sites and incision site using a 22-gauge needle in a sterile fashion prior to skin incision.
Study NCT03915639 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-incisional injection
Description: The surgeons are planned to inject the cocktail mixture or ropivacaine to muscles and the subcutaneous tissue beneath the fixation sites and incision site using a 22-gauge needle in a sterile fashion prior to skin incision.
Study NCT05176275 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-RP25
Description: The proliferation and distribution of CD19 CAR-T cells in lymphoma patients were investigated by PET / CT after injection of 68Ga-NOTA-RP25
Study NCT05831111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.1
Description: Sterile liquid for injection
Study NCT05831111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1195.2
Description: Sterile liquid for injection
Study NCT05831111 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1189
Description: Sterile liquid for injection
Study NCT05831111 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT05925933 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention
Description: high protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods.
Study NCT05925933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: high protein diet (carbohydrates 45%, protein 29%, and fat 26%) over 8-week periods.
Study NCT05751122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic flex cast with neurodevelopmental treatment
Description: Neurodevelopmental therapy in combination with dynamic flex cast to treat experimental group.~Three times a week, 1 hour session per day.~Dynamic flex casting is casting which manipulate bone alignment and maintains range of motion or sustained stretch. Casting will be changed weekly for 3 months.~Neuro developmental approach is individualized treatment which is attuned to each child's specific problems, aims and goals.~Key elements in NDT are: facilitation (using sensory inputs to improve motor performance), management of compensatory motor behavior, and an overall management strategy (a 24-hour interdisciplinary management approach) NDT involves task specific postures and movements.
Study NCT05751122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rigid Ankle foot Orthosis with neurodevelopmental treatment
Description: Rigid ankle foot orthosis will be applied to ankle joint at the start of intervention.~Neurodevelopmental treatment will be applied to both groups with protocol; Three times a week, 1 hour session per day.~Assessment on 1st day,6th week and 12th week